Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial

Scott Kopetz, Danielle A. Murphy, Jie Pu, Fortunato Ciardiello, Jayesh Desai, Eric Van Cutsem, Harpreet Singh Wasan, Takayuki Yoshino, Hedieh Saffari, Xiaosong Zhang, Phineas Hamilton, Tao Xie, Rona Yaeger, Josep Tabernero

Open source

DOI
10.1038/s41591-024-03235-9
Published
2024-09-23
Container
Nature Medicine
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41591-024-03235-9,
  title = {Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial},
  author = {Scott Kopetz and Danielle A. Murphy and Jie Pu and Fortunato Ciardiello and Jayesh Desai and Eric Van Cutsem and Harpreet Singh Wasan and Takayuki Yoshino and Hedieh Saffari and Xiaosong Zhang and Phineas Hamilton and Tao Xie and Rona Yaeger and Josep Tabernero},
  year = {2024},
  journal = {Nature Medicine},
  doi = {10.1038/s41591-024-03235-9},
  url = {https://doi.org/10.1038/s41591-024-03235-9}
}

RIS

TY  - JOUR
TI  - Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
AU  - Scott Kopetz
AU  - Danielle A. Murphy
AU  - Jie Pu
AU  - Fortunato Ciardiello
AU  - Jayesh Desai
AU  - Eric Van Cutsem
AU  - Harpreet Singh Wasan
AU  - Takayuki Yoshino
AU  - Hedieh Saffari
AU  - Xiaosong Zhang
AU  - Phineas Hamilton
AU  - Tao Xie
AU  - Rona Yaeger
AU  - Josep Tabernero
PY  - 2024
JO  - Nature Medicine
DO  - 10.1038/s41591-024-03235-9
UR  - https://doi.org/10.1038/s41591-024-03235-9
ER  - 

APA

Kopetz, S., Murphy, D. A., Pu, J., Ciardiello, F., Desai, J., Cutsem, E. V., Wasan, H. S., Yoshino, T., Saffari, H., Zhang, X., Hamilton, P., Xie, T., Yaeger, R., & Tabernero, J. (2024). Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03235-9

Source records